Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Black Diamond Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Black Diamond Therapeutics, Inc.’s stock price such as:

• Black Diamond Therapeutics, Inc.’s current stock price and volume
• Why Black Diamond Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for BDTX from analysts
• BDTX’s stock price momentum as measured by its relative strength

About Black Diamond Therapeutics, Inc. (BDTX)

Before we jump into Black Diamond Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Black Diamond Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Black Diamond Therapeutics, Inc..

Black Diamond Therapeutics, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Black Diamond Therapeutics, Inc.’s stock price was $3.820.

Black Diamond Therapeutics, Inc. is up 1.06% from its previous closing price of $3.780.

During the last market session, Black Diamond Therapeutics, Inc.’s stock traded between $3.800 and $3.900. Currently, there are approximately 56.93 million shares outstanding for Black Diamond Therapeutics, Inc..

Black Diamond Therapeutics, Inc.’s price-earnings (P/E) ratio is currently at 10.1, which is low compared to the Biotechnology industry median of 19.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Black Diamond Therapeutics, Inc. Stock Price History

Black Diamond Therapeutics, Inc.’s (BDTX) price is currently down 1.29% so far this month.

During the month of November, Black Diamond Therapeutics, Inc.’s stock price has reached a high of $4.940 and a low of $3.620.

Over the last year, Black Diamond Therapeutics, Inc. has hit prices as high as $4.940 and as low as $1.195. Year to date, Black Diamond Therapeutics, Inc.’s stock is up 78.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Black Diamond Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there was 1 analyst who downgraded Black Diamond Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Black Diamond Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Black Diamond Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Black Diamond Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Black Diamond Therapeutics, Inc. (BDTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Black Diamond Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Black Diamond Therapeutics, Inc. has a weighted four-quarter relative price strength of 13.35%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Black Diamond Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Black Diamond Therapeutics, Inc. Stock Price: Bottom Line

As of November 28, 2025, Black Diamond Therapeutics, Inc.’s stock price is $3.820, which is up 1.06% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Black Diamond Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.